Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4297 - Patterns of treatment and outcome of fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/Her2-negative (HER2-) metastatic breast cancer (MBC): a real life multicenter Italian experience


10 Oct 2016


Poster display


Raffaella Palumbo


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


R. Palumbo1, A. Ferzi2, A. Gambaro3, F. Sottotetti4, L. Licata1, C. Teragni1, B. Tagliaferri1, E. Pozzi1, A. Bernardo1

Author affiliations

  • 1 Usd Oncologia, Fondazione S. Maugeri IRCCS, 27100 - Pavia/IT
  • 2 Medical Oncology, Ospedale Civile di Legnano, Legnano/IT
  • 3 Medical Oncology, Ospedale Luigi Sacco, Milano/IT
  • 4 Oncologia Medica, IRCCS Fondazione Salvatore Maugeri, 27100 - Pavia/IT


Abstract 4297


Fulvestrant 500 mg (F500) is a well-established therapeutic option for HR + /HER2- MBC postmenopausal patients (pts) who had previously progressed on hormonal therapy. Available data on F500 use in routine clinical practice are lacking. This retrospective multicenter observational study was conducted to describe the patterns of treatment and outcome of F500 in the real life setting,


Data of postmenopausal HR + /HER2- MBC pts who received F500 from January 2011 to December 2014 were collected from institutional databases of 4 Italian Centers. The primary study aim was to analyze progression-free survival (PFS) and Clinical Benefit Rate (CBR: complete response [CR] + partial response [PR] + stable disease [SD] > 24 weeks); secondary endpoints included overall survival (OS) and safety profile.


490 pts were included in the study, 480 were evaluable. F500/month was given as 1st up to 7th treatment line: 1st line in 24% of pts, 2nd line in 35%, >3rd in 41%. 306 pts received the drug upon progression of disease (PD) on prior endocrine treatment, 92 and 68 as maintenance therapy following 1st or 2nd line chemotherapy, respectively; 21% of pts had de novo metastatic disease. Median age: 66 years (range 56-81); visceral metastases: 32%; ECOG PS = 1: 62%. Median of cycles administered: 14 (range 6-28). At a median follow-up of 18 months (range 6-38) median PFS was 11.6 months (range 8.1-16.2: 12.5 in 1st line, 11.4 in 2nd line, 9.2 in >3 lines), CBR was 68.6% (8.8% CR, 21.6 PR, 38,2 SD> 24 weeks). No differences in CBR (67.8% vs 69.1%) and PFS (11.5 vs 11.6 months) were observed between pts receiving F500 as maintenance therapy and those treated at PD on prior therapy. Median OS was 44.2 months (range 35-NR). More frequent toxicities did not exceed grade 1 NCI-CTC: local injection site pain (11.2%), joint disorders (6.2%), hot flushes (4.9%).


Our real word experience confirm that F500 can safely be offered to most women with HR + /HER2- MBC, with interesting expectations of PFS and CBR and good safety profile, producing similar outcomes as both upon PD treatment and maintenance therapy.

Clinical trial identification

Legal entity responsible for the study

Raffaella Palumbo


IRCCS Fondazione S. Maugeri


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings